Metastatic Breast Cancer Treatment After Abemaciclib-Related Liver Injury — Case 2
This breast cancer diagnosis at a glance
- Stage at diagnosis
- Stage IV
- Sex
- female
- Treatment
- hormone therapy and targeted therapy
- Outcome
- Care Ongoing
Treatment course, step by step
- She started letrozole with abemaciclib.
- Abemaciclib was stopped after severe liver injury on day 27.
- Endocrine therapy was changed from letrozole to fulvestrant.
- After liver recovery, she switched to palbociclib without recurrent liver dysfunction.
What happened, in summary
A 71-year-old woman with metastatic breast cancer started letrozole and abemaciclib. On day 27, her ALT rose to 380 IU/L. Abemaciclib was discontinued, and the ALT level fell by about half over the next month. Her endocrine treatment was also changed from letrozole to fulvestrant. Abemaciclib was not reintroduced. After liver recovery, she began palbociclib, allowing CDK4/6 inhibitor therapy to continue. Her ALT remained stable after the change, with no recurrence of the severe liver dysfunction. The switch allowed her treatment plan to continue while avoiding another episode of severe liver injury.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Stage 4 Breast Cancer 295 stories
- Abemaciclib for Breast Cancer 25 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer